Brief: Hutchmed (China) Says Astrazeneca Submits US NDA For Orpathys Plus Tagrisso
29/09/2026 02:50
BRIEF-Hutchmed (China) Says Astrazeneca Submits US NDA For Orpathys Plus Tagrisso Sept 29 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
ASTRAZENECA SUBMITS US NDA FOR ORPATHYS PLUS TAGRISSO IN MET-DRIVEN EGFR-MUTATED LUNG CANCER
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsKras: EGFR-Antibody licensing deal with GSK closes
Brief: Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals